Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Empowered Funds LLC increased its Arrowhead Pharmaceuticals stake by 661.6% in the first quarter, adding 119,202 shares to own 137,220 shares valued at approximately $8.6 million. Institutional investors collectively hold 62.61% of ARWR.
• Analysts maintain a generally positive outlook, with nine Buy, three Hold, and one Sell rating; the consensus is “Moderate Buy” with a $97.33 price target.
• Arrowhead’s latest quarter showed revenue of $75.25 million, up 171% year over year and above estimates, but the company reported a larger-than-expected loss of $1.36 per share.

Empowered Funds LLC grew its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 661.6% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 137,220 shares of the biotechnology company's stock after acquiring an additional 119,202 shares during the quarter. Empowered Funds LLC owned about 0.10% of Arrowhead Pharmaceuticals worth $8,604,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Tsfg LLC bought a new position in Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $25,000. Optiver Holding B.V. grew its position in Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company's stock worth $26,000 after purchasing an additional 186 shares during the period. iSAM Funds UK Ltd purchased a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at $29,000. First Horizon Corp purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at $32,000. Finally, WPG Advisers LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 384.8% during the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company's stock valued at $36,000 after buying an additional 431 shares during the period. 62.61% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ARWR has been the subject of several research analyst reports. Piper Sandler reaffirmed an "overweight" rating and issued a $126.00 price objective (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. B. Riley Financial increased their target price on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a "buy" rating in a report on Thursday, July 30th. HC Wainwright raised their target price on Arrowhead Pharmaceuticals from $115.00 to $120.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Sanford C. Bernstein boosted their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a "market perform" rating in a research note on Wednesday, May 13th. Finally, Leerink Partners upped their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a "market perform" rating in a research report on Wednesday, June 17th. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $97.33.

Arrowhead Pharmaceuticals Trading Up 1.2%

NASDAQ:ARWR opened at $86.64 on Friday. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. The firm has a market capitalization of $12.20 billion, a price-to-earnings ratio of -38.51 and a beta of 1.27. Arrowhead Pharmaceuticals, Inc. has a one year low of $18.73 and a one year high of $95.49. The business has a fifty day moving average price of $81.37 and a 200-day moving average price of $72.15.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The company had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. During the same period in the prior year, the business posted ($1.26) earnings per share. Arrowhead Pharmaceuticals's revenue for the quarter was up 171.0% compared to the same quarter last year. Sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source